Proprietary & ConfidentialThis material is proprietary to My Life Spark P.C. Unauthorized use, reproduction, or distribution is strictly prohibited.

Blog··11 min read

The Clinician Content Gap Map: What Cancer Survivorship Professionals Search For and Rarely Find

A field-mapped audit of the queries oncology, primary-care, and survivorship-program leads type into search — and why the answers matter most when they route through cardio-oncology.

Search-log audits across oncology, primary-care, and survivorship-program forums surface the same recurring queries — and the same wall of pamphlet-grade results. This is a field-mapped content-gap map for the professionals carrying survivorship follow-up, framed against the cardio-oncology through-line that decides whether these gaps become adverse events.

How the gap map was built

We reviewed public search queries from oncology and primary-care communities, ASCO Connection threads, and survivorship-program listservs across the last 18 months, then tagged each query by (a) whether primary-guidance answers exist, (b) whether the top search results surface them, and (c) whether the answer plausibly changes management. Queries scoring low on (b) and high on (c) are the gap.

The cardio-oncology through-line was not an editorial choice — it is what the data returned. Six of the top ten gap queries route into cardiac surveillance, cardiotoxicity recognition, or shared-care ownership between oncology, cardio-oncology, and primary care.

Gap 1: Anthracycline cumulative-dose thresholds in adult survivors

The query: 'how much doxorubicin is safe long-term.' The pamphlet answer: '450–550 mg/m² is the classical threshold.' The gap: modern regimens sit well below the threshold, yet late LVEF drift still occurs — the clinician question is really 'what surveillance cadence do I run at 240 mg/m² in a 35-year-old at year seven?'

The Life Spark cascade builder answers with an exposure-scaled schedule (baseline echo or CMR, then 2- and 5-year follow-up with earlier repeat for symptoms, arrhythmia, or GLS decline > 15% relative). Cardio-oncology referral triggers are embedded so the primary-care clinician does not have to guess.

Gap 2: HER2-directed therapy monitoring after treatment ends

The query: 'trastuzumab cardiac follow-up after therapy stops.' The pamphlet answer: 'monitor during treatment.' The gap: post-treatment guidance is dispersed across cardio-oncology consensus documents and rarely reaches primary care.

The workspace surfaces a two-arm cadence — asymptomatic vs. mid-treatment LVEF drop — with an explicit escalation trigger and a cardio-oncology referral script.

Gap 3: Immune-checkpoint-inhibitor myocarditis after the last dose

The query: 'ICI myocarditis timing.' The pamphlet answer: 'usually within 6 weeks.' The gap: bimodal presentation includes late cases months to a year after the last dose. Primary-care visits are where these late presentations show up, and troponin is not on the reflex order set.

The recognition pattern is a short reflex bundle (troponin, BNP, ECG, low-threshold cardiology referral) triggered by unexplained fatigue, dyspnea, or palpitations in any ICI-exposed survivor.

Gap 4: Radiation-induced heart disease decades later

The query: 'mediastinal radiation heart disease screening.' The pamphlet answer: 'monitor for late effects.' The gap: pericardial, valvular, coronary, and conduction-system disease each have distinct surveillance cadences and each is under-run in adult survivors of pediatric Hodgkin lymphoma and left-breast radiation before the modern era.

The gap map links to a treatment-era-adjusted surveillance schedule and a pre-visit worksheet that the survivor can complete and hand over.

Gap 5: Deprescribing after long-term survivorship

The query: 'how do I taper years of PRNs safely in a cancer survivor.' The pamphlet answer: '(none).' The gap: no primary guideline addresses the specific interaction between long-term PRN accumulation and residual cardiotoxicity risk.

The Life Spark deprescribing worksheet is structured for exactly this conversation — stop/taper logic, contraindication reminders, and documentation lines that survive an audit.

Gap 6: Cognitive and distress screens that fit a 20-minute visit

The query: 'brief cognitive screen for chemo brain.' The pamphlet answer: 'consider neuropsych referral.' The gap: primary care needs a five-minute screen that flags who benefits from full neuropsych, not a 90-minute battery.

The toolkit surfaces the NCCN Distress Thermometer and a lightweight cognitive screen with trending — so the referral is data-driven, not a shot in the dark.

Gap 7: The transition-of-care artifact itself

The query: 'survivorship care plan template.' The pamphlet answer: a static PDF with 40 empty fields. The gap: the artifact needs to be generated from real data — treatment exposures, cumulative doses, current symptoms — not typed by hand.

Life Spark generates the plan from the patient's own tool entries so the surveillance section is specific, not generic.

Gap 8: Shared-care ownership between oncology, cardio-oncology, and primary care

The query: 'who orders the survivor's echo.' The pamphlet answer: 'the treating team.' The gap: after year five, there often isn't one. See the shared-care model post for the ownership matrix.

Gap 9: Financial-toxicity workflows a clinic can actually run

The query: 'financial toxicity screening tool.' The pamphlet answer: 'screen at every visit.' The gap: what to do with a positive screen. The Life Spark financial worksheet routes to charity-care windows, appeal templates, and survivor-only benefit programs.

Gap 10: A hand-off shape a modern EHR will accept

The query: 'FHIR survivorship bundle.' The pamphlet answer: '(implementation guides are draft).' The gap: teams need a working shape today. Life Spark ships a FHIR R4 bundle (Condition, MedicationStatement, Observation, CarePlan) that lands cleanly in modern EHR intake.

Frequently asked questions

Is this list derived from primary guidance or opinion?
Each gap is anchored to NCCN, ASCO, or COG-LTFU primary guidance where it exists. Where guidance is thin (deprescribing after long-term survivorship, shared-care ownership after year five), we surface consensus-document positions and mark them as such.
How is this different from a standard survivorship review article?
Review articles describe the science. This map is action-first: every gap links to a working artifact — a cascade, worksheet, or hand-off — that a clinician can put in front of the next patient this week.
Where do I start if I only have 20 minutes?
Open the cardio-oncology surveillance cascade for one recent survivor, run it against the last note, and see which orders were missed. That single exercise usually surfaces the highest-yield workflow change.
Back to top